Citius OncologyCTOR 10 Dividend Yield % is 0.00% as of Jun. 26, 2026. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 516 Drug Manufacturers companies, Citius Oncology ranks worse than 193798.26% on this metric.
As of today (2026-06-26), the Trailing Annual Dividend Yield of Citius Oncology is 0.00%.
The historical rank and industry rank for Citius Oncology's Dividend Yield % or its related term are showing as below:
CTOR's Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.005 * Ranked among companies with meaningful Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for Citius Oncology's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTOR vs INCR, BGM, CPIX: Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Citius Oncology Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Citius Oncology's Dividend Yield % falls into.
Citius Oncology (CTOR) has a Dividend Yield % of 0.00% as of Jun. 26, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Citius Oncology and its competitors. According to the industry distribution chart, Citius Oncology ranks #999999 out of 516 companies in the Drug Manufacturers industry.
Is Citius Oncology's Dividend Yield % too high?
Citius Oncology's current Dividend Yield % is 0.00%. Based on the distribution chart, Citius Oncology ranks #999999 out of 516 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's Dividend Yield % compare to INCR and BGM?
According to the Drug Manufacturers industry distribution chart, Citius Oncology ranks #999999 out of 516 companies for Dividend Yield %. This places Citius Oncology in the lower half of its industry. The industry median Dividend Yield % is 2.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 2.01, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Citius Oncology and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 2.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Citius Oncology's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current Dividend Yield % of 0.00%. The current Dividend Yield % is 0.00%. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Citius Oncology (CTOR), the current Dividend Yield % is 0.00% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score
Get the complete analysis for CTOR
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTOR has been successfully added to your 
